OMER vs. NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS
Should you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.
Omeros vs.
Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Omeros is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 5.3% of Nektar Therapeutics shares are held by insiders. Comparatively, 12.3% of Omeros shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -180.70%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.
Nektar Therapeutics currently has a consensus price target of $4.50, indicating a potential upside of 581.82%. Omeros has a consensus price target of $22.50, indicating a potential upside of 598.76%. Given Omeros' higher probable upside, analysts plainly believe Omeros is more favorable than Nektar Therapeutics.
Omeros received 113 more outperform votes than Nektar Therapeutics when rated by MarketBeat users. Likewise, 70.65% of users gave Omeros an outperform vote while only 70.58% of users gave Nektar Therapeutics an outperform vote.
Nektar Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500.
In the previous week, Omeros had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 15 mentions for Omeros and 14 mentions for Nektar Therapeutics. Omeros' average media sentiment score of 0.17 beat Nektar Therapeutics' score of -0.10 indicating that Omeros is being referred to more favorably in the news media.
Summary
Omeros beats Nektar Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Omeros News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:OMER) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy OMER Stock Free OMER Stock Alerts